What is Angioslide?
Founded in 2005 by Eran Hirszowicz and Amos Nahir, Angioslide is a privately-held medical device company dedicated to providing physicians with cost-effective, innovative products for emboli management during vascular interventions. The company's flagship PROTEUS device family is the only FDA-cleared device designed to capture and remove embolic particles dislodged at the lesion site in peripheral arteries. This focus on patient safety and procedural efficiency positions Angioslide as a key player in the interventional cardiology and radiology markets.
How much funding has Angioslide raised?
Angioslide has raised a total of $24.9M across 3 funding rounds:
Series A
$4M
Series B
$14.6M
Series C
$6.3M
Series A (2006): $4M with participation from Viola Partners
Series B (2013): $14.6M led by Ofer-Hi Tech, Triventures, and Agate Medical investments
Series C (2013): $6.3M supported by TriVentures and Viola Partners
Key Investors in Angioslide
TriVentures
TriVentures is a global venture capital fund that invests in early-stage companies with innovative breakthroughs in healthcare and other industries, focusing on bio-convergence and data-driven technologies.
Viola Partners
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets and supporting Israeli entrepreneurs through a multi-strategy investment approach across various technology sectors.
Ofer-Hi Tech
Ofer-Hi Tech is an entity that has participated in Angioslide's Series B funding round, indicating a strategic interest in the company's medical device technology.
What's next for Angioslide?
With a history of securing substantial investment rounds, including Series A, B, and C financing, Angioslide appears to be in a growth phase, likely scaling its operations and expanding its product reach. The recent major strategic investment suggests a strong validation of its technology and market potential. Future endeavors will likely involve further clinical validation, broader commercialization efforts, and potentially the development of next-generation emboli management solutions to address unmet clinical needs in vascular procedures.
See full Angioslide company page
